Evidence map›Paper›PMID 38952157›Full record

ReviewCurrent cancer drug targets2025

The Role of Epigenetic Mechanisms in the Treatment of GI Cancers.

Ali Shahini, Amirhossein Imani, Amirali Reyhani, Ghazaleh Khalili-Tanha, Elnaz Ghorbani, Hamid Fiuji, Ibrahim Saeed Al-Hayawi, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A Ferns and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ali ShahiniStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirhossein ImaniStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirali ReyhaniStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh Khalili-TanhaMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Elnaz GhorbaniMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid FiujiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ibrahim Saeed Al-HayawiCollege of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsBrighton ' Sussex Medical School, Division of Medical Education, Falmer, Brighton, SussexBN1 9PH, UK.
Elham NazariMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences MEDICAL.REC.1400.679
6 · The paper itself

Abstract

Epigenetic mechanisms have been shown to play a critical role in the development and progression of gastrointestinal [GI] cancers. These mechanisms involve modifications to DNA and histones that can alter gene expression patterns and may contribute to the initiation and progression of cancers. In recent years, epigenetic therapies have emerged as a promising approach to treating GI cancers. These therapies target specific epigenetic modifications, such as DNA methylation and histone acetylation, to restore normal gene expression patterns and inhibit cancer cell growth. Several epigenetic drugs have been approved for the treatment of GI cancers. Moreover, the use of epigenetic therapies in combination with other treatments, such as chemotherapeutic agents, is being studied to improve treatment outcomes. We have provided an overview of the role of epigenetic mechanisms in GI cancer treatment aimed to focus on recent evidence of the use of epigenetic agents in clinical and preclinical GI cancer studies, including gastric, esophageal, hepatic, pancreatic, and colorectal cancers. Overall, the role of epigenetic mechanisms in GI cancer treatments is an active area of research with the potential to improve patients' treatment outcomes and advance cancer treatment strategies.

Indexed as

Antineoplastic AgentsEpigenesis, GeneticGastrointestinal NeoplasmsAnimalsDNA MethylationGene Expression Regulation, NeoplasticHistonesHumansAntineoplastic AgentsHistonesDNADNA methylationEpigeneticgastrointestinal cancerhistone acetylation.treatment

Identifiers

PMID38952157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.